Journal
STEM CELLS TRANSLATIONAL MEDICINE
Volume 5, Issue 11, Pages 1550-1561Publisher
WILEY
DOI: 10.5966/sctm.2016-0024
Keywords
Oligodendrocytes; Multiple sclerosis; Nonhuman primates; Myelination
Categories
Funding
- Dutch MS Research Foundation [MS08-637, MS09-694]
- EUPRIM-Net under EU Contract of the 7th Framework Program [262443]
- Netherlands Organisation for Scientific Research (NWO) [ZonMW 91111.006]
Ask authors/readers for more resources
Fast remyelination by endogenous oligodendrocyte precursor cells (OPCs) is essential to prevent axonal and subsequent retrograde neuronal degeneration in demyelinating lesions in multiple sclerosis (MS). In chronic lesions, however, the remyelination capacity of OPCs becomes insufficient. Cell therapy with exogenous remyelinating cells may be a strategy to replace the failing endogenous OPCs. Here, we differentiated human induced pluripotent stem cells (hiPSCs) into OPCs and validated their proper functionality in vitro as well as in vivo in mouse models for MS. Next, we intracerebrally injected hiPSC-derived OPCs in a nonhuman primate (marmoset) model for progressive MS; the grafted OPCs specifically migrated toward the MS-like lesions in the corpus callosum where they myelinated denuded axons. hiPSC-derived OPCs may become the first therapeutic tool to address demyelination and neurodegeneration in the progressive forms of MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available